HCW Biologics Inc
HCWB9.021USD
-1.029-10.24%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
401.81MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über HCW Biologics Inc Unternehmen
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The Company is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.
Unternehmensinformationen
Unternehmens-codeHCWB
Name des UnternehmensHCW Biologics Inc
IPO-datumJul 20, 2021
Gegründet am2018
CEODr. Hing C. Wong, Ph.D.
Anzahl der mitarbeiter36
WertpapierartOrdinary Share
GeschäftsjahresendeJul 20
Addresse2929 N Commerce Pkwy
StadtMIRAMAR
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl33025
Telefon19548422024
Websitehttps://hcwbiologics.com/
Unternehmens-codeHCWB
IPO-datumJul 20, 2021
Gegründet am2018
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Hing C. Wong, Ph.D.
Dr. Hing C. Wong, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
493.86K
+23.05%
Ms. Rebecca Byam
Ms. Rebecca Byam
Chief Financial Officer
Chief Financial Officer
43.01K
+24.49%
Mr. Scott T. Garrett
Mr. Scott T. Garrett
Independent Chairman of the Board
Independent Chairman of the Board
12.08K
+80.41%
Mr. Lee Flowers
Mr. Lee Flowers
Senior Vice President of Business Development
Senior Vice President of Business Development
5.72K
+20.23%
Mr. Gary M. Winer
Mr. Gary M. Winer
Independent Director
Independent Director
2.73K
+543.06%
Dr. Peter Rhode, Ph.D.
Dr. Peter Rhode, Ph.D.
Chief Scientific Officer, Vice President of Clinical Operations
Chief Scientific Officer, Vice President of Clinical Operations
1.94K
+0.05%
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
896.00
+0.11%
Mr. Rick S. Greene
Mr. Rick S. Greene
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Hing C. Wong, Ph.D.
Dr. Hing C. Wong, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
493.86K
+23.05%
Ms. Rebecca Byam
Ms. Rebecca Byam
Chief Financial Officer
Chief Financial Officer
43.01K
+24.49%
Mr. Scott T. Garrett
Mr. Scott T. Garrett
Independent Chairman of the Board
Independent Chairman of the Board
12.08K
+80.41%
Mr. Lee Flowers
Mr. Lee Flowers
Senior Vice President of Business Development
Senior Vice President of Business Development
5.72K
+20.23%
Mr. Gary M. Winer
Mr. Gary M. Winer
Independent Director
Independent Director
2.73K
+543.06%
Dr. Peter Rhode, Ph.D.
Dr. Peter Rhode, Ph.D.
Chief Scientific Officer, Vice President of Clinical Operations
Chief Scientific Officer, Vice President of Clinical Operations
1.94K
+0.05%
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionäre
Update-Zeit: 19 hours ago
Update-Zeit: 19 hours ago
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
Wong (Hing C)
43.96%
Armistice Capital LLC
4.50%
Byam (Rebecca)
3.83%
Garrett (Scott T)
1.08%
Avantax Planning Partners, Inc
0.62%
Other
46.01%
Aktionärsstatistik
Aktionäre
Anteil
Wong (Hing C)
43.96%
Armistice Capital LLC
4.50%
Byam (Rebecca)
3.83%
Garrett (Scott T)
1.08%
Avantax Planning Partners, Inc
0.62%
Other
46.01%
Art
Aktionäre
Anteil
Individual Investor
50.05%
Hedge Fund
4.57%
Investment Advisor
1.54%
Investment Advisor/Hedge Fund
1.32%
Research Firm
0.03%
Other
42.48%
Institutionelle Beteiligung
Update-Zeit: Tue, Mar 4
Update-Zeit: Tue, Mar 4
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
37
530.40K
48.29%
+53.17K
2024Q4
37
23.10M
51.86%
+2.14M
2024Q3
33
21.13M
54.31%
+156.07K
2024Q2
33
21.19M
54.45%
+322.27K
2024Q1
34
20.93M
57.88%
+1.69M
2023Q4
33
19.30M
53.71%
+122.06K
2023Q3
33
19.17M
53.35%
-2.58K
2023Q2
33
22.70M
63.26%
-3.42M
2023Q1
32
22.37M
62.46%
-3.36M
2022Q4
32
22.28M
62.20%
-3.33M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Wong (Hing C)
16.05M
35.73%
--
--
Nov 22, 2024
Armistice Capital LLC
2.02M
4.5%
+2.02M
--
Dec 31, 2024
Byam (Rebecca)
1.38M
3.08%
--
--
Apr 15, 2024
Garrett (Scott T)
267.86K
0.6%
+142.86K
+114.29%
Apr 15, 2024
Avantax Planning Partners, Inc
279.54K
0.62%
--
--
Dec 31, 2024
The Vanguard Group, Inc.
37.68K
0.08%
--
--
Dec 31, 2024
Geode Capital Management, L.L.C.
181.96K
0.4%
-1.30K
-0.71%
Dec 31, 2024
Flowers (Lee)
190.24K
0.42%
+71.43K
+60.12%
Feb 20, 2024
Cresset Asset Management, LLC
131.99K
0.29%
--
--
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Tue, May 6
Update-Zeit: Tue, May 6
Name
Anteil
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten